Viva Biotech Holdings's revenue for the
six
months ended in Dec. 2023 was HK$1,108 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2,358 Mil.
Viva Biotech Holdings's Revenue per Share for the
six
months ended in Dec. 2023 was HK$0.52.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.17.
Warning Sign:
Viva Biotech Holdings revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Viva Biotech Holdings was -16.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 30.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 58.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 8 years, Viva Biotech Holdings's highest 3-Year average Revenue per Share Growth Rate was 101.80% per year. The lowest was 30.20% per year. And the median was 65.00% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Viva Biotech Holdings's Revenue
For the Biotechnology subindustry, Viva Biotech Holdings's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's Revenue distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's Revenue falls into.
Viva Biotech Holdings Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$2,358 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Viva Biotech Holdings Revenue Related Terms
Thank you for viewing the detailed overview of Viva Biotech Holdings's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Viva Biotech Holdings (HKSE:01873) Business Description
Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation ("CDMO") and commercialisation services segment includes contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01873 has been successfully added to your 